Moderna (MRNA) Soars 179% as Melanoma Therapy Candidate Rewrites Growth Story

The Yahoo Finance report, published August 23, says Moderna rose 179% as investors reassessed its growth prospects around a melanoma-therapy candidate. No trial readout, regulatory milestone, commercial forecast, or other supporting clinical detail was provided in the supplied material, so the magnitude and durability of the move cannot be independently grounded here.

The contrast with the company’s latest reported financial profile is material: FY 2025 revenue was $1.9B, down 39.9% year over year, while diluted EPS was $-7.26 and net margin was -145.2%. The candidate therefore sits against a business still reporting sharply lower sales and substantial losses.

The next datapoints are the candidate’s clinical efficacy and safety evidence, the timing and scope of any regulatory filings, and whether management provides a commercial path that can offset the current revenue decline. Without those details, the headline establishes investor enthusiasm but not the asset’s probability of success or its contribution to earnings.